Clinical Studies and Case Reports

On this site you will find clinical studies with cannabis or single cannabinoids in different diseases and case reports on the use of cannabis by patients.
You may search for diseases (indications), authors, medication, study design (controlled study, open trial, case report etc.) and other criteria.

[Back to Overview]  [IACM Homepage]

TitleEffect of Sublingual Application of Cannabinoids on Intraocular Pressure: A Pilot Study.
Author(s)Tomida I, Azuara-Blanco A, House H, Flint M, Pertwee RG, Robson PJ.
Journal, Volume, IssueJ Glaucoma 2006 15(5):349-353.
Major outcome(s)Significant reduction of intraocular pressure

PURPOSE: The purpose of this study was to assess the effect on intraocular pressure (IOP) and the safety and tolerability of oromucosal administration of a low dose of delta-9-tetrahydrocannabinol (Delta-9-THC) and cannabidiol (CBD). PATIENTS AND METHODS: A randomized, double-masked, placebo-controlled, 4 way crossover study was conducted at a single center, using cannabis-based medicinal extract of Delta-9-THC and CBD. Six patients with ocular hypertension or early primary open angle glaucoma received a single sublingual dose at 8 AM of 5 mg Delta-9-THC, 20 mg CBD, 40 mg CBD, or placebo. Main outcome measure was IOP. Secondary outcomes included visual acuity, vital signs, and psychotropic effects. RESULTS: Two hours after sublingual administration of 5 mg Delta-9-THC, the IOP was significantly lower than after placebo (23.5 mm Hg vs. 27.3 mm Hg, P=0.026). The IOP returned to baseline level after the 4-hour IOP measurement. CBD administration did not reduce the IOP at any time. However, the higher dose of CBD (40 mg) produced a transient elevation of IOP at 4 hours after administration, from 23.2 to 25.9 mm Hg (P=0.028). Vital signs and visual acuity were not significantly changed. One patient experienced a transient and mild paniclike reaction after Delta-9-THC administration. CONCLUSIONS: A single 5 mg sublingual dose of Delta-9-THC reduced the IOP temporarily and was well tolerated by most patients. Sublingual administration of 20 mg CBD did not reduce IOP, whereas 40 mg CBD produced a transient increase IOP rise.

Dose(s)5 mg
Duration (days)1
Participants6 patients with increased intraocular pressure
DesignControlled study
Type of publicationMedical journal
Address of author(s)Department of Ophthalmology, Aberdeen Royal Infirmary, School of Medical Sciences, Institute of Medical Sciences, University of Aberdeen, UK, Cannabinoid Research Institute, Magdalen Centre, Oxford Science Park, Oxford OX4 4GA
Full text

[Back to Overview]  [IACM Homepage]